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Abstract The etiopathology and neurobiology of obses-
sive–compulsive disorder (OCD) are not fully understood.
As for altered circadian rhythms associated with OCD,
hormonal dysregulation and a delayed sleep phase have
come into the focus of research. The novel antidepressant
agomelatine is able to resynchronize circadian rhythms
and the augmentative administration of this compound
has been shown to be of benefit in some OCD patients who
are refractory to common forms of pharmacotherapy.
Adjunctive chronotherapy might also enhance the outcome
in treatment-refractory OCD. The present review summa-
rises the findings regarding circadian abnormalities in
OCD.
Keywords Obsessive–compulsive disorder (OCD) 
Circadian rhythm  Hormone dysregulation  Delayed sleep
phase  Agomelatine  Chronotherapy
Introduction
Obsessive–compulsive disorder (OCD) is a common
chronic neuropsychiatric disorder which results in marked
distress and impairment of social and occupational func-
tioning. OCD is characterized by clinically significant
recurrent, intrusive and disturbing thoughts (obsessions)
and/or repetitive stereotypic behaviors (compulsions)
which are usually associated with anxiety or dread. The
disorder can be inherited (for review see Pauls 2010;
Walitza et al. 2010) or acquired. Approximately 2 to 3 %
of the population are affected by OCD and an early age of
symptom onset has been observed in many patients (Nes-
tadt et al. 2000; Flament et al. 1988; Valleni-Basile et al.
1994). Obsessive/compulsive symptoms have been shown
to increase at times of stress (Findley et al. 2003) and
stressful events may precede the onset of OCD (e.g., Toro
et al. 1992).
There is no established pathology for OCD and putative
pathophysiological alterations have been inferred from
abnormalities as observed using structural and functional
neuroimaging. A review of the neurobiology of OCD is
given by Grados and Wilcox (2007). A possible role of
abnormal circadian rhythms in OCD is mainly based on
three lines of evidence, i.e. (1) hormonal dysregulation in
subjects with OCD, (2) a delayed sleep phase in some
individuals with OCD and (3) effective augmentation
treatment with agomelatine in patients who are refractory
to commonly used forms of OCD pharmacotherapy. Ago-
melatine has been shown to be able to resynchronize cir-
cadian rhythms in patients with mental disorders.
Hormonal abnormalities in OCD
The interest in possible alterations of circadian rhythms in
psychiatric disorders has put hormonal dysregulation into
the focus of scientific investigations, since many hormones
are released according to circadian patterns. In a recent
review, Kalsbeek et al. (2012) have described the current
view on the control by the suprachiasmatic nucleus of the
daily rhythm in the activity of the hypothalamic–pituitary–
adrenal (HPA) axis.
K. W. Lange (&)  K. M. Lange  J. Hauser
Department of Experimental Psychology, University
of Regensburg, 93040 Regensburg, Germany
e-mail: klaus.lange@psychologie.uni-regensburg.de;
Klaus.Lange@ur.de
K. W. Lange  L. Tucha  O. Tucha
Department of Developmental and Clinical Neuropsychology,
University of Groningen, Groningen, The Netherlands
123
J Neural Transm (2012) 119:1077–1083
DOI 10.1007/s00702-012-0805-z
Individuals with OCD have been reported to show
alterations in hormone levels, including the concentrations
of cortisol (Catapano et al. 1992; Monteleone et al. 1994),
corticotrophin releasing hormone (CRH) (Altemus et al.
1992), dehydroepiandrosterone (DHEA) and its sulfated
metabolite DHEA-S (Bigos et al. 2009), adrenocorticotro-
phic hormone (ACTH) (Bailly et al. 1994), growth hor-
mone (Kluge et al. 2007a, b), vasopressin (Altemus et al.
1992), oxytocin (Leckman et al. 1994) and melatonin
(Catapano et al. 1992; Monteleone et al. 1994).
The findings regarding the functioning of the HPA axis
are inconsistent. Elevated CRH concentrations in the
cerebrospinal fluid of patients with OCD (Altemus et al.
1992) suggest an increase in HPA axis activity. However,
other studies failed to find this increase and similar CRH
levels were observed in OCD patients and healthy control
subjects (Chappell et al. 1996). A hyperactivity of the HPA
axis is also indicated by the finding that a lack of inhibition
of cortisol secretion after a dexamethasone suppression test
can be found in some patients with OCD (Cottraux et al.
1984; Catapano et al. 1990). These observations could,
however, not be confirmed by other authors (Coryell et al.
1989; Jenike et al. 1987; Lieberman et al. 1985; Lucey
et al. 1992; Vallejo et al. 1988). Further information con-
cerning HPA axis activity can be derived from secretion
profiles of the stress hormones ACTH and cortisol. In
comparison with control subjects, circadian cortisol
secretion profiles were reported to be preserved but ele-
vated in OCD patients (Catapano et al. 1992; Monteleone
et al. 1994). Nocturnal plasma cortisol and ACTH levels
were shown to be significantly increased in individuals
with OCD compared to healthy controls, while the secre-
tion patterns over time were similar in both groups (Kluge
et al. 2007a, b). These findings are in accordance with
earlier results indicating a hyperactive HPA axis (e.g.,
Altemus et al. 1992; Cottraux et al. 1984). They do not
corroborate, however, the hypothesis of a decrease in
pituitary sensitivity due to elevated CRH levels (Bailly
et al. 1994), since ACTH was not reduced in patients with
OCD.
Hyperactivity of the HPA axis, commonly observed in
adult OCD patients, has also been shown to be present in
children and adolescents with OCD. In comparison to a
control group of school children, young individuals with
OCD displayed higher early-morning basal cortisol levels
with no difference between the groups in the late-morning
and evening assessments (Gustafsson et al. 2008). The
cortisol levels in children and adolescents with OCD
diminished in response to a psychological stressor (i.e.,
exposure therapy), compared to a positive response in the
control group (Gustafsson et al. 2008). The non-response in
young OCD patients may be another example of HPA
dysregulation.
Patients with OCD have been shown to suffer more
severely from stress related to daily life than healthy
individuals (Coles et al. 2005; Findley et al. 2003; Tarumi
and Tashiiro 2004). Both physical and psychological stress
can activate the HPA axis (de Kloet et al. 2005). Since
patients with OCD perceive their obsessive thoughts as
beyond their control, this lack of control may be a stressor
leading to a chronically hyperactive HPA axis. As to the
psychobiology of OCD, the increase in the activity of the
HPA axis may be regarded as a result of stress, i.e. HPA
alterations may be a consequence of non-specific anxiety
and therefore a state rather than a trait feature of OCD.
However, the resistance of the HPA axis to therapy (Millet
et al. 1999; Khanna et al. 2001) points in another direction.
A hyperactive HPA axis might play a role in the patho-
physiology of OCD. For example, neurobiological models
of OCD (Rosenberg and Keshavan 1998) posit an impor-
tant role of a dysfunctional anterior cingulate gyrus (ACG)
which has been suggested to be part of an overactive
action-monitoring system and to be involved in the path-
ophysiology of OCD (Ursu et al. 2003). Structural and
functional alterations of the ACG in patients with OCD
(Rauch et al. 1994; Rosenberg and Keshavan 1998;
Szeszko et al. 2004, 2005; Ursu et al. 2003; Viard et al.
2005) and observations suggesting a critical role of the
ACG in the regulation of the HPA axis (Diorio et al. 1993;
Herman et al. 2005; MacLullich et al. 2006) underline the
possibility of a two-way interaction between ACG and
HPA axis. For a more detailed summary of possible links
between HPA axis and OCD, see Kluge et al. (2007a, b).
In OCD subjects, nocturnal growth hormone (GH)
secretion has been shown to be altered, i.e. the release of
sleep onset-related GH was blunted (Kluge et al. 2007a).
This finding appears to be compatible with central neuro-
transmitter alterations assumed in OCD, indicating an
influence at hypothalamic or higher levels. In a single
individual with OCD, the circadian patterns of DHEA and
cortisol have been reported to be markedly different from
control subjects, with DHEA and DHEA-S levels being
substantially higher in the OCD subject (Bigos et al. 2009).
This preliminary finding requires the assessment of larger
patient samples. A dysregulation of DHEA and DHEA-S
has also been reported in other mood and anxiety disorders
(Eser et al. 2006; Le Melledo and Baker 2002, 2004). For
example, subjects with major depression show increased
diurnal plasma DHEA (Heuser et al. 1998) and both DHEA
and DHEA-S have been found to decrease with the
remission of depression (Fabian et al. 2001). The relative
amounts of DHEA and/or DHEA-S appear to be main-
tained between blood and brain (Bernardi et al. 2005;
Guazzo et al. 1996). Increased DHEA/DHEA-S blood
levels should therefore indicate elevated DHEA/DHEA-S
concentrations in the brain. DHEA and DHEA-S are
1078 K. W. Lange et al.
123
modulators of GABAA (Le Melledo and Baker 2004;
Majewska 1992; Majewska et al. 1990; Reddy and Kulk-
arni 1997) and N-methyl-D-aspartate (NMDA) receptors
(Compagnone and Mellon 2000; Rupprecht 1997) and are
also involved in NMDA-induced norepinephrine release
(Monnet et al. 1995). Since altered central norepinephrine
levels appear to be associated with other anxiety disorders
(Sullivan et al. 1999), DHEA dysregulation may play a role
in OCD-related anxiety.
Alterations in the circadian secretion of melatonin have
been reported in OCD. In medication-free individuals with
OCD, the night-time peak of melatonin concentrations was
shown to be markedly reduced in comparison with control
subjects and occurred with a delay of 2 h (Monteleone
et al. 1994). These abnormalities were more pronounced in
patients with more severe OCD symptoms as assessed with
the Yale-Brown Obsessive Compulsive Scale (Y-BOCS,
Goodman et al. 1989). A delay in peak melatonin would
usually result in a phase delay of sleep.
Delayed sleep phase syndrome in OCD
Mental disorders are frequently accompanied by sleep
disturbance. The few studies examining possible sleep
disturbance in OCD have reported contradictory findings,
including an undisturbed sleep pattern observed in some
studies (Hohagen et al. 1994) and sleep disruption found in
others (Insel et al. 1982; Rapoport et al. 1981). Investiga-
tions in both adults (Insel et al. 1982) and adolescents
(Rapoport et al. 1981) with OCD found a reduced total
sleep duration, a decrease in stage 2 sleep and a shortened
rapid eye movement (REM) latency. Stage 4 sleep and
slow-wave sleep were reported to be increased (Rapoport
et al. 1981) or decreased (Insel et al. 1982) in OCD. The
OCD patients in these studies (Hohagen et al. 1994; Insel
et al. 1982; Rapoport et al. 1981) concomitantly suffered
from depression. In a recent study, the sleep variables did
not differ between patients with OCD without comorbid
major depression and healthy matched control subjects
(Kluge et al. 2007a). Out of ten patients, three subjects,
who appeared to be more severely affected by OCD than
the others, exhibited sleep onset REM periods (Kluge et al.
2007a). In comparison with control subjects, Bobdey et al.
(2001) observed no significantly different sleep pattern in
OCD patients without depression. A small subgroup of
these patients, however, went to bed and arose much later
than normal. This delayed sleep phase syndrome (DSPS)
results in daytime sleepiness and a considerable disruption
of social and occupational functioning (Weitzman et al.
1981). The prevalence of DSPS in the general adult pop-
ulation is estimated at 0.17–0.72 % (Schrader et al. 1993).
Elevated rates of 7.3 % in adolescents (American Psychi-
atric Association 1994) and up to 10 % in children (Smits
et al. 2001) have been reported. Differences between the
sexes were not found (Dagan and Eisenstein 1999). Almost
50 % of adult individuals with DSPS have been reported to
show psychiatric symptoms (Weitzman et al. 1981) with
depressive disorder being the most common psychiatric
concomitant (Zammit 1997).
A retrospective study reported a possible association
between OCD and DSPS (Mukhopadhyay et al. 2004). A
more recent retrospective study identified 17.6 % of 187
cases with severe, enduring OCD who were also affected
by DSPS (Mukhopadhyay et al. 2008). In a prospective
study, individuals with therapy-refractory OCD showed an
increased rate of delayed sleep phase, i.e. 42 % out of a
total of 31 patients with severe resistant OCD suffered
from DSPS (Turner et al. 2007). No other sleep parameter
apart from the timing of sleep was observed to be signifi-
cantly different. Patients with DSPS were significantly
more likely to be male, were younger and showed more
severe OCD than those with a normal sleep phase
(Mukhopadhyay et al. 2008; Turner et al. 2007). The
delayed sleep phase in the patients reported by Turner et al.
(2007) was not due to patients performing bedtime rituals
or taking longer to fall asleep. The DSPS in OCD patients
was associated with an increase in disablement in occu-
pational and social functioning (Turner et al. 2007). It is,
however, unclear whether this reflected the shifted sleep
pattern or the more severe OCD.
Circadian rhythms are entrained by temporal cues and
environmental zeitgebers such as the light–dark cycle.
Various stressors or behavioral patterns may cause dis-
ruptions in social routines and as a consequence in bio-
logical rhythms according to the social zeitgeber theory
(Grandin et al. 2006). OCD patients presenting with com-
plex ritualistic behavior at home may be insufficiently
exposed to light in the morning. In addition, lack of activity
and social withdrawal may hinder the daily resetting of the
biological clock. These behavioral patterns may eventually
result in a phase delay of sleep. Weitzman et al. (1981)
argue, however, that DSPS is the cause and not the result of
psychological symptoms in mental disorders, since the
treatment of the sleep disorder can lead to a marked
improvement in psychological functioning. Other authors
support the idea that DSPS precedes and may therefore
contribute to the development of mental disorder (Dagan
et al. 1996, 1998). With regard to personality disorders,
Dagan et al. (1996, 1998) have suggested that a mismatch
between a person’s biological clock and the environment
may cause social and emotional difficulties. As for indi-
viduals with OCD, however, it needs to be noted that
delayed sleep phase developed after the onset of OCD in
the patients reported by Turner et al. (2007). In addition,
OCD patients who responded satisfactorily to fluoxetine
treatment showed no difference in biological parameters,
Circadian rhythms in obsessive–compulsive disorder 1079
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such as temperature and plasma levels of cortisol and
melatonin, as assessed before and after treatment (Millet
et al. 1999; Monteleone et al. 1995).
A recent report has described a patient with severe OCD
who had failed prior trials of pharmacotherapy and psy-
chotherapy and whose symptoms were associated with
delayed bedtimes and delays in the time she initiated her
night-time compulsions (Coles and Sharkey 2011). Later,
at the time of initiation, her compulsions were associated
with more time spent performing her compulsions. Cog-
nitive-behavioral techniques commonly used for OCD with
adjunctive chronotherapy (i.e., advancement of sleep-wake
schedule) were associated with substantial improvement of
her compulsive behavior at night. Further studies are nee-
ded in order to establish whether chronotherapy may
enhance the outcome in treatment-refractory OCD, partic-
ularly in individuals with night-time compulsions.
Augmentation with agomelatine for the treatment
of OCD
The pharmacotherapy with selective serotonin reuptake
inhibitors (SRIs) is well established for the treatment of
OCD. Forty to 60 % of patients with OCD, however, do
not respond satisfactorily to SRIs (Bloch et al. 2006; da
Rocha and Correa 2007; Pallanti et al. 2002). The low-dose
augmentative administration of dopamine antagonists such
as risperidone has been shown to be effective in some
patients who are refractory to SRIs (Bloch et al. 2006).
Recent reports have presented evidence that the aug-
mentation with agomelatine may also be helpful in OCD
patients who are resistant to common forms of pharmaco-
therapy and do not respond to augmentation with other
compounds. Agomelatine is a novel antidepressant which
is a melatonergic agonist at melatonin 1 (MT1) and MT2
receptors and acts as a selective serotonin antagonist at the
5-hydroxytryptamine (HT)2C receptor, while it does not
appear to affect monoamine uptake (de Bodinat et al.
2010). The blockade of 5-HT2C receptors is of interest
since these receptors are involved in mood control and
stress response. Serotonin has been shown to be synthe-
sized according to a circadian pattern (e.g. Sanchez et al.
2008) and the suprachiasmatic nucleus, the dominant force
for the circadian rhythms controlling sleep and temperature
(Refinetti and Menaker 1992), has a major input of sero-
tonin-containing neurons originating in the raphe nuclei
(Bosler and Beaudet 1985). In humans, agomelatine
appears to possess positive phase-shifting properties. An
advance in the sleep phase, a decline in body temperature,
and a release of melatonin have been found following the
administration of agomelatine (de Bodinat et al. 2010).
In a small case series, agomelatine at a dose of 50 mg/
day was assessed in six patients, with and without other
psychiatric comorbidities, who had been refractory to
previous treatments with SRIs (Fornaro 2011). Three out of
six patients showed a clinical improvement with a symp-
tom reduction of at least 35 % as compared to the pre-
treatment Y-BOCS scores which is regarded as a
significant therapy response in current clinical trials (Pal-
lanti et al. 2002). Another adult patient with clomipramine-
refractory OCD who did not respond to augmentation with
risperidone and aripiprazole was reported to show clinical
improvement with agomelatine (da Rocha and Correa
2011). The ability of agomelatine to resynchronize circa-
dian rhythms may demonstrate the important role of a
disruption of these rhythms found in OCD. Since the reg-
ulation of the serotonergic system is circadian, a resyn-
chronization of this system may affect serotonergic
dysfunction known to be of importance in OCD (Wulff
et al. 2010). Further investigations are needed to assess the
efficacy of agomelatine as an augmentation strategy for
therapy-refractory OCD.
Conclusion
The etiopathology and neurobiology of OCD are not fully
understood. Hormonal dysregulation and a delayed sleep
phase in patients with OCD point to a possible role of
abnormal circadian rhythms in the pathophysiology of the
disorder. The etiology of delayed sleep phase in individuals
with OCD and its interaction with the core symptoms of
OCD with regard to clinical function and disability remain
to be investigated. In particular, prospective longitudinal
assessments of sleep phase in OCD are needed. The con-
tribution of comorbid depression is difficult to disentangle
from that of OCD. Sleep disturbance is a core feature of
major depression which is also the most common comorbid
disorder of OCD (Weissman et al. 1994). It is therefore
possible that DSPS occurring in OCD is related to
comorbid depression. A number of concomitant clinical
features that may be referable to bipolarity (Centorrino
et al. 2006) may account for treatment refractoriness in
some OCD cases. Future studies, therefore, should further
elucidate the overlap between OCD and depression. The
efficacy of agomelatine and the importance of a resyn-
chronization of circadian rhythms in the therapy of OCD
require further investigations. Adjunctive chronotherapy
might also enhance the outcome in treatment-refractory
OCD. In addition, the investigation of novel treatments
such as light therapy or the administration of melatonin
might be of interest.
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